Back to Search Start Over

ATR inhibition enables complete tumour regression in ALK-driven NB mouse models

Authors :
Joanna Szydzik
Dan E. Lind
Badrul Arefin
Yeshwant Kurhe
Ganesh Umapathy
Joachim Tetteh Siaw
Arne Claeys
Jonatan L. Gabre
Jimmy Van den Eynden
Bengt Hallberg
Ruth H. Palmer
Source :
Nature Communications, Vol 12, Iss 1, Pp 1-18 (2021)
Publication Year :
2021
Publisher :
Nature Portfolio, 2021.

Abstract

Effective therapeutic options are still needed in neuroblastoma treatment. Here, the authors, through a comprehensive proteomics analysis, identify ATR as a potential therapeutic target of neuroblastoma and demonstrate the efficacy of the ATR inhibitor BAY1895344 in combination with the ALK tyrosine kinase inhibitor lorlatinib.

Subjects

Subjects :
Science

Details

Language :
English
ISSN :
20411723
Volume :
12
Issue :
1
Database :
Directory of Open Access Journals
Journal :
Nature Communications
Publication Type :
Academic Journal
Accession number :
edsdoj.06e9a92a8a164615981fa91b32e6d409
Document Type :
article
Full Text :
https://doi.org/10.1038/s41467-021-27057-2